# Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF

Study · id `cardio:ct-nct07687212` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07687212](<https://clinicaltrials.gov/study/NCT07687212>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07687212

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 162 participants.

## Technical summary

Registry record NCT07687212. Randomized; quadruple masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2027-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 162 participants (planned count; ClinicalTrials.gov record NCT07687212, source copy `cardio:ctgov-nct07687212-2026-07-07`, retrieved 2026-10-31)
- Planned start: 2026-07 (anticipated) (ClinicalTrials.gov record NCT07687212, source copy `cardio:ctgov-nct07687212-2026-07-07`, retrieved 2026-10-31)
- Primary completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT07687212, source copy `cardio:ctgov-nct07687212-2026-07-07`, retrieved 2026-10-31)
- Completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07687212, source copy `cardio:ctgov-nct07687212-2026-07-07`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07687212, source copy `cardio:ctgov-nct07687212-2026-07-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07687212-2026-07-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
- Condition: Heart Failure, Preserved Ejection Fraction
- Intervention (Drug): Henggliflozin Combined with Probiotics
- Intervention (Drug): Henggliflozin
- Intervention (Drug): double placebo
- Lead sponsor: The First Affiliated Hospital of Air Force Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital of Air Force Medical University (`cardio:org-the-first-affiliated-hospital-of-air-force-medical-d06ce1`)

## Provenance

Content hash: 8c48379cf94ff44c8ed3dccdc27b34ae46c0ced728518981a103fa8a3eb098b6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
